2025-12-20 - Analysis Report
Okay, here's a comprehensive analysis of Merck & Co. Inc. (MRK) based on the provided data:

**1) Return Rate Comparison**

*   **Company Overview:** Merck & Co. Inc. is a global pharmaceutical company focused on developing and marketing innovative medicines and vaccines.
*   **MRK Cumulative Return:** 20.29%
*   **S&P 500 (VOO) Cumulative Return:** 100.88%
*   **Divergence:**
    *   Current: -82.8
    *   Relative Divergence: 16.8

**Analysis:** MRK has significantly underperformed the S&P 500 over the period considered.  The divergence is -82.8%, meaning the gap between MRK's returns and the S&P 500's is substantial. The Relative Divergence of 16.8 indicates that the current divergence is near the lower end of its historical range. This suggests that the underperformance might be considered significant when viewed historically, potentially indicating an opportunity for future catch-up or a sign of fundamental issues.

**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 1.0% | 68.5% | -28.0% | 0.0 | 134.1 |
| 2016-2018  | 36.0% | 69.8% | 21.0% | -0.0 | 182.1 |
| 2017-2019  | 40.0% | 69.8% | 18.0% | 0.3 | 216.8 |
| 2018-2020  | 16.0% | 79.6% | -8.0% | 0.3 | 195.0 |
| 2019-2021  | 2.0% | 79.6% | -44.0% | 0.7 | 191.4 |
| 2020-2022  | 15.0% | 79.6% | 16.0% | 0.7 | 277.1 |
| 2021-2023  | 33.0% | 79.6% | 31.0% | 0.3 | 272.3 |
| 2022-2024  | -4.0% | 79.6% | -25.0% | 0.2 | 248.5 |
| 2023-2025  | -29.0% | 71.5% | -94.0% | 1.8 | 252.5 |

**Analysis:**

*   **CAGR:** Fluctuating CAGR indicates inconsistent growth over the analyzed periods. The recent negative CAGR is a concern.
*   **MDD (Maximum Drawdown):** High MDD values suggest significant volatility and potential for large losses.
*   **Alpha:**  Alpha measures the investment's performance relative to a benchmark (likely the S&P 500). Negative Alpha values in several periods demonstrate underperformance compared to the benchmark. The extremely negative Alpha for 2023-2025 is a major red flag.
*   **Beta:** Beta measures the stock's volatility relative to the market.  A Beta around 0-0.3 generally suggests the stock is less volatile than the market, but the recent Beta surge to 1.8 indicates significantly increased volatility and sensitivity to market movements.
*   **Cap(B):** Market capitalization has generally increased over time but has recently stagnated.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 101.09
*   **Previous Close:** 100.69
*   **Change:** 0.4
*   **5-day SMA:** 99.898
*   **20-day SMA:** 100.5595
*   **60-day SMA:** 91.8107

**Analysis:**

*   The current price is slightly above the previous close, indicating a small upward movement.
*   The 5-day SMA is below the 20-day SMA, which is above the 60-day SMA. This suggests a recent short-term upward trend, but the longer-term trend is still uncertain. The price is well above the 60-day SMA, indicating a potential support level at that point.

**3) RSI, PPO, and Expected Return**

*   **MRI (Market Risk Indicator):** 0.7 (Medium Investment)
*   **RSI:** 50.55
*   **PPO:** -0.4883
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (10 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** 3.1 (+): 단기상승 (Short-term increase)
*   **Expected Return (%):** -52.3

**Analysis:**

*   The MRI suggests a medium level of investment risk.
*   The RSI of 50.55 indicates a neutral momentum, neither overbought nor oversold.
*   The negative PPO (-0.4883) suggests the price is slightly below its moving average, hinting at potential weakness.
*   The "Hybrid Signal" is providing a conflicting signal, recommending a full buy based on a "very safe" designation. This contradicts the negative expected return.
*   The 20-day relative divergence change indicates a recent upward trend.
*   The highly negative Expected Return (-52.3%) is a major cause for concern.  This suggests that, based on current conditions, long-term investment in MRK is projected to result in a significant loss compared to the S&P 500.

**4) Recent News & Significant Events**

*   **Drug-Pricing Bargains:** The news about drug-pricing bargains could impact future revenue.
*   **FDA Fast-Track Catalysts:** Potential FDA fast-track approvals could be positive catalysts for the stock.
*   **Stock Holdings Boosted:** Increased stock holdings by Talbot Financial LLC indicate institutional confidence.
*   **Valuation Shift:**  The article about a valuation shift after pipeline updates and a stock jump suggests recent positive developments.
*   **Strong Growth Stock:**  The Nasdaq article highlighting MRK as a strong growth stock is a positive signal.
*   **Deep Pipeline and Cash Flow Strength:** The Seeking Alpha article emphasizing MRK's deep pipeline and cash flow strength supports a bullish outlook.

**Analysis:** The news is a mixed bag.  The articles highlighting pipeline strength, cash flow, and positive analyst sentiment provide a bullish view. However, the drug-pricing bargains and articles questioning valuation suggest potential headwinds.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (Mean rating: 1.90)
*   **Opinions:** 26
*   **Target Price (avg/high/low):** 110.04 / 139.00 / 83.00
*   **Recent Rating Changes:** No recent changes noted (indicated by empty parentheses).

**Analysis:** The analyst consensus is "Buy" with a significant number of opinions. The average target price of $110.04 suggests an upside potential from the current price.  The lack of recent rating changes implies that analysts' opinions are relatively stable.

**5) Recent Earnings Analysis**

| 날짜       | EPS  | 매출         |
|------------|------|--------------|
| 2025-11-05 | 2.32 | 17.28 B$     |
| 2025-08-05 | 1.76 | 15.81 B$     |
| 2025-05-02 | 2.01 | 15.53 B$     |
| 2024-11-06 | 1.25 | 16.66 B$     |
| 2025-11-05 | 1.25 | 16.66 B$     |

**Analysis:**

*   EPS has generally increased over the last few quarters.
*   Revenue has also shown growth, although there are slight fluctuations. The most recent quarter (2025-11-05) shows the highest EPS and Revenue.
*   The provided quarterly table has an duplication of dates (2025-11-05).

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $17.28B   | 77.69%        |
| 2025-06-30   | $15.81B   | 77.50%        |
| 2025-03-31   | $15.53B   | 77.98%        |
| 2024-12-31   | $15.62B   | 75.50%        |
| 2024-09-30   | $16.66B   | 75.51%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE       |
|--------------|-----------|-----------|
| 2025-09-30   | $51.85B   | 11.16%    |
| 2025-06-30   | $48.99B   | 9.04%     |
| 2025-03-31   | $48.34B   | 10.51%    |
| 2024-12-31   | $46.31B   | 8.08%     |
| 2024-09-30   | $44.50B   | 7.09%     |

**Analysis:**

*   **Revenue and Profitability:** Both revenue and profit margins have been consistently high, suggesting a strong and efficient business model. The recent increase in revenue is particularly positive.
*   **Capital and Profitability:** Equity has been steadily increasing, indicating growth in the company's assets. ROE (Return on Equity) has also been improving, reflecting better profitability relative to shareholders' equity.

**7) Comprehensive Analysis (Summary)**

*   **Underperformance:** MRK has significantly underperformed the S&P 500, with a large negative divergence.
*   **Volatility:** High MDD and a recent spike in Beta suggest increased volatility and risk.
*   **Mixed Signals:** Analyst consensus is "Buy," and news highlights pipeline strength, but the Expected Return is highly negative, and recent Alpha is very poor.
*   **Financial Strength:** The company shows strong revenue, profit margins, and increasing equity, indicating a solid financial foundation.
*   **Conflicting Signals:** The hybrid signal suggests the stock is in a buy position, whereas the expected return is very negative.
*   **Technical Analysis:** The recent stock price is above its 5, 20, and 60 day SMA's, indicating an uptrend.

**Conclusion:**

The analysis presents a mixed picture of MRK. While the company has a strong financial foundation, analyst support, and recent positive news catalysts, the significant underperformance relative to the S&P 500, the extremely negative Expected Return, and rising Beta are major concerns. The negative Alpha, especially recently, also warrants close scrutiny.

**Recommendation:**

Given the conflicting signals, a cautious approach is warranted. While the analyst consensus and positive news might attract some investors, the significant underperformance and negative expected return raise red flags. Further investigation into the reasons behind the negative expected return and recent performance is crucial before making any investment decision. The investor should also closely monitor the stock's volatility and market sensitivity due to the high Beta value.

Investors should carefully weigh the bullish and bearish signals before making any decisions. It is important to understand what's driving the negative expected return despite the positive analyst ratings and pipeline strength. Is it a temporary setback, or does it reflect a fundamental change in the company's prospects?

This analysis should not be taken as financial advice. Always conduct your own thorough research and consider your individual risk tolerance before making any investment decisions.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.